Dave is a microbiologist who has been involved in many of tranScrip’s drug development and medical affairs projects on antibacterial, antifungal and antiviral agents. He has over 40 years’ industry experience including GlaxoSmithKline and Chiron Biopharmaceuticals.
Dave joined Beecham Pharmaceuticals in 1976 and remained with the company through its various transformations eventually becoming GlaxoSmithKline. During this time, he spent 12 years in antibiotic discovery of ß-lactamase inhibitors and novel antibacterial agents, seven years in global clinical development and eight years in medico-marketing and medical communications.
In 2004, Dave joined Chiron Biopharmaceuticals as European Director of Microbiology and was part of the team responsible for the approval and launch of daptomycin (Cubicin®) in Europe. He provided microbiology support to the European Marketing Group and local operating companies during the Cubicin launch phase, and provided microbiology expertise to the inhaled tobramycin development team.
In 2006, Dave became an independent microbiology consultant providing consultancy services to Pharmaceutical and Biotech companies before joining tranScrip Partners in January 2010.
During his career, Dave has gained experience in the development of antibacterial agents for hospital and community use, including TB and C. difficile infection, topical agents for cSSTI and Bacterial Vaginosis, antiviral agents to treat HSV, VZV, Hepatitis B and C, and CMV infection and antifungal agents to treat systemic fungal diseases. He has provided microbiological expertise to pharmaceutical companies during the preparation and submission of MAAs and NDAs, and has been involved with pre- and peri-launch activities including scientific training of affiliate and sales staff.